Evidence map›Paper›PMID 34711014›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.

Dalia A Elsers, Mahmoud R A Hussein, Mohammed Hassan Osman, Ghada A Mohamed, Ghada Hosny

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dalia A ElsersFaculty of Medicine, Assiut University, Egypt.ORCID 0000-0003-1330-0486
Mahmoud R A HusseinDepartment of Pathology Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0000-0001-9366-2211
Mohammed Hassan OsmanDepartment of Head and Neck Surgery, Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0000-0002-1805-7828
Ghada A MohamedDepartment of Internal Medicine Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0000-0002-8884-2071
Ghada HosnyFaculty of Medicine, Assiut University, Egypt.ORCID 0000-0002-9362-8862
Assiut University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe follicular-patterned thyroid lesions (FPTLs) include hyperplastic nodules (HN), follicular adenoma (FA), non-invasive follicular neoplasm with papillary-like nuclear features (NIFTP), follicular carcinoma (FC), and the follicular variant of papillary carcinoma (FVPTC). Sometimes the pathologists cannot accurately separate these lesions from each others on a histological basis.

aimsTo evaluate the utility of immunohistochemistry in the diagnosis of FPTLs. MATERIALS AND

methodsImmunohistochemical analysis, incorporating 83 cases of histologically confirmed FPTLs out of which 20 carcinomas, 51 benign FPTLs (38 HN and 13 FA), and 12NIFTP were separated from each others using four immunostains (HBME-1, CK19, Galectin-3, and CD56).

resultsWe found statistically significantly more frequent expression of HBME-1, CK19, Galectin-3 proteins in carcinomas as compared to benign FPTLs (p = <0.01). HBME-1 and Galectin-3 were the most sensitive markers for the diagnosis of malignant FPTLs (75%). Galectin-3 was the most specific marker for the diagnosis of carcinoma (90.3%).

conclusionsThe histomorphological features remain the cornerstone of the diagnosis of FPTN. Although HBME-1, Galectin-3, and CK19 immunostains have some diagnostic value in the separation of malignant from benign FPTLs, they are variably expressed in the benign and malignant FPTLs. No single immunostain has sufficient sensitivity and specificity and therefore their diagnostic use is controversial. Future studies are mandated to find more reliable markers that can separate between benign and malignant FPTLs.

Indexed as

Adenocarcinoma, FollicularAdenomaAdolescentAdultAntigens, NeoplasmBiomarkers, TumorCD56 AntigenFemaleGalectin 3HumansImmunohistochemistryKeratin-19MaleMiddle AgedThyroid Cancer, PapillaryThyroid NeoplasmsAntigens, NeoplasmBiomarkers, TumorCD56 AntigenGalectin 3HBME-1 antigenKeratin-19CD56CK19Galectin 3HBME-1NIFTP

Identifiers

PMID34711014
PMCPMC8858236
OpenAlexW3208323054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.